| Q57055224 | A Statistical Perspective on Prevention Trials: A View from the Women’s Health Initiative |
| Q35092002 | A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients |
| Q34161156 | A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? |
| Q37041238 | Alcohol consumption and breast cancer risk among postmenopausal women following the cessation of hormone therapy use: the California Teachers Study |
| Q38542170 | Association of endometriosis and breast cancer: mini review of the literature |
| Q37321697 | Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause |
| Q30980873 | Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. |
| Q44864645 | Breast Cancer Incidence and Hormone Replacement Therapy in Canada |
| Q26777289 | Breast cancer risk factors |
| Q36937185 | Breast tenderness after initiation of conjugated equine estrogens and mammographic density change |
| Q35866374 | Changing concepts: Menopausal hormone therapy and breast cancer |
| Q57988321 | Climacteric commentaries |
| Q37209821 | Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study |
| Q36143058 | Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial |
| Q30659580 | Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data |
| Q33371496 | Data analysis methods and the reliability of analytic epidemiologic research |
| Q43836825 | Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast |
| Q38384869 | Embedding clinical interventions into observational studies |
| Q56779064 | Epidemiology, Lifestyle, and Environmental Factors |
| Q38982905 | Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial |
| Q34392623 | Estrogen-induced apoptosis of breast epithelial cells is blocked by NO/cGMP and mediated by extranuclear estrogen receptors. |
| Q43276874 | Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? |
| Q36113238 | Exogenous estrogen protects mice from the consequences of obesity and alcohol |
| Q35557640 | Genetic variants in the MRPS30 region and postmenopausal breast cancer risk |
| Q55521896 | Genetic variation in sensitivity to estrogens and breast cancer risk. |
| Q38011779 | Have we come full circle - or moved forward? The Women's Health Initiative 10 years on. |
| Q36851595 | Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial |
| Q34315268 | Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. |
| Q37909897 | Hormone replacement therapy and the risk of breast cancer |
| Q40071035 | Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium |
| Q33566626 | Mammographic screening and risk factors for breast cancer |
| Q37370478 | Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort |
| Q34315478 | Menopausal hormone therapy and cancer: changing clinical observations of target site specificity |
| Q34115930 | Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study |
| Q40283293 | Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study. |
| Q33894784 | Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview |
| Q34420014 | Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke |
| Q30451123 | Postmenopausal hormone therapy: an Endocrine Society scientific statement. |
| Q38082563 | Postmenopausal hormone therapy: risks and benefits |
| Q50053097 | Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling. |
| Q31171709 | Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions |
| Q36069532 | Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women |
| Q33739861 | Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. |
| Q91322300 | Sex hormones and stroke: Beyond estrogens |
| Q37153415 | Should hormone replacement therapy be used in postmenopausal women for voiding dysfunction? |
| Q34161400 | The 2012 hormone therapy position statement of: The North American Menopause Society |
| Q34975284 | The HRT controversy: observational studies and RCTs fall in line |
| Q30485457 | The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk |
| Q33718863 | The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort |
| Q90661837 | The modulation of estrogen-induced apoptosis as an interpretation of the women's health initiative trials |
| Q93043410 | Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence |
| Q37989179 | Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause |
| Q46064533 | Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy |
| Q37438789 | Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer |
Search more.